Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson with an Outperform rating and $190 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson announces results from analyses of Phase 2 DAHLIAS study
- Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz
- J&J sues government agency over payment terms for 340B hospitals, STAT says
- Johnson & Johnson MedTech receives IDE approval for Ottava system
- Johnson & Johnson: FDA grants nipocalimab Breakthrough Therapy designation